Market Samachar
CNBC
·
GLOBAL
·
Replimune to resubmit twice-rejected drug for approval after FDA shakeup
As reported by CNBC
Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.
▸ MARKET SAMACHAR VIEW
NEUTRAL
Read full article on CNBC ↗
Market Samachar is a news aggregator. This article was originally published by
CNBC. Tap the button above to read the full story on their site.
🔥 Hot Now
Top stories across markets in the last hour
More from Market Samachar